Manufactures active pharmaceutical ingredients (APIs) and offers contract development/manufacturing services to global pharma companies.
Manufactures active pharmaceutical ingredients (APIs) and offers contract development/manufacturing services to global pharma companies.
Sells generic active ingredients (the part of a medicine that works) in volume to generic drugmakers, where customers qualify the plant and product before ordering, and does custom synthesis under contract for innovator companies at higher value. The founding family leads the company.
In one line: A mid-sized Indian API/CDMO player.
Moat: narrow (regulatory licence, process know-how). US FDA/EU-approved API plants and chemistry expertise support long-term supply contracts.
Headquarters: Hyderabad, India · Founded: 1984 · Employees: 3,881
Size Neuland Laboratories (NEULANDLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $2.95B, the 296th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹21,455 on 18 Nov 2026.
Performance Over six months the shares gained 27.8%, against -8.4% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 50.5% over the last twelve months (peer median +9.4%); the operating margin is 26.0% (peer median 11.3%).
Valuation It trades at 63.4× forward earnings against a peer median of 22.1× (3rd most expensive of 17).
Capital Return on invested capital runs 6.9 points above its cost of capital (16.4% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹23.1B | ₹20.0B | ₹14.5B | ₹15.3B | ₹11.8B |
| Revenue growth | — | +37% | -5% | +31% | — |
| Gross profit | ₹7.65B | ₹6.33B | ₹3.82B | ₹4.99B | ₹3.07B |
| EBITDA | ₹7.05B | ₹5.61B | ₹3.12B | ₹4.46B | ₹2.69B |
| Net income | ₹4.53B | ₹3.64B | ₹2.60B | ₹3.00B | ₹1.64B |
| Free cash flow | n/a | -₹589M | ₹1.13B | ₹1.12B | ₹1.60B |
| Capital expenditure | n/a | ₹3.97B | ₹2.06B | ₹1.44B | ₹661M |
| Total debt | ₹3.42B | ₹3.01B | ₹1.57B | ₹954M | ₹1.28B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Neuland Laboratories NEULANDLAB.NS | $2.95B | +28% | +50% | 26% | 63.4× | n/a |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
| Laurus Labs LAURUSLABS.NS | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% |
| Piramal Pharma PPLPHARMA.NS | $3.40B | +38% | +9% | 3% | 150.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEULANDLAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.6% | -1.4% | 5th highest of 21 |
| 6-month return | +27.8% | -8.4% | 4th highest of 21 |
| Distance from 52-week high | -11.4% | -34.8% | 4th highest of 21 |
| Revenue growth (TTM) | +50.5% | +9.4% | 3rd highest of 20 |
| Operating margin | 26.0% | 11.3% | 3rd highest of 20 |
| Forward P/E | 63.4× | 22.1× | 3rd most expensive of 17 |
| ROIC minus cost of capital | +6.9 pp | +1.4 pp | 6th highest of 17 |
| EV / EBITDA | 38.9× | 18.7× | 2nd most expensive of 8 |
| Net debt / EBITDA | -0.1× | -1.9× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |